SCHEMBL4090082

SCHEMBL4090082

CC(C)(C)OCC(=O)NN

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.41
ALDH1A1 P00352 6/20 0.38
OGG1 O15527 2/20 0.38
AAK1 Q2M2I8 1/20 0.38
KDM4E B2RXH2 6/20 0.36
KDM5C P41229 1/20 0.36
PHF8 Q9UPP1 1/20 0.36
KDM2A Q9Y2K7 1/20 0.36
KDM6B O15054 1/20 0.34
KDM4A O75164 1/20 0.34
KDM5A P29375 1/20 0.34
MAPT P10636 1/20 0.34
LMNA P02545 2/20 0.33
GAA P10253 1/20 0.33
APLNR P35414 1/20 0.32
MAPK1 P28482 1/20 0.31
AOC2 O75106 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL444607 0.78 LMNA (0.36) ALDH1A1AAK1KDM4EMAPTLMNA
SCHEMBL14681741 0.78 TPI1 (0.43) AAK1KDM4EKDM5CPHF8KDM2A
SCHEMBL9962283 0.76 TSHR (0.44) ALDH1A1MAPTLMNAGAAMAPK1
SCHEMBL21401211 0.76 ALDH1A1 (0.38) CTSDALDH1A1OGG1KDM4EKDM5C
SCHEMBL22402927 0.76 MCL1 (0.44) ALDH1A1KDM4ELMNAGAA
SCHEMBL9911967 0.76 CTSD (0.38) CTSDALDH1A1OGG1
SCHEMBL19010423 0.74 MCL1 (0.40) ALDH1A1AAK1KDM4ELMNAMAPK1
SCHEMBL13225634 0.74 TSHR (0.36) AAK1APLNRMAPK1
SCHEMBL27641005 0.74 MAOA (0.40) ALDH1A1AAK1MAPTGAA
SCHEMBL12859140 0.73 LMNA (0.41) ALDH1A1KDM4EMAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 CTSD 4644/4885ALDH1A1 3165/4885OGG1 2210/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 CTSD 4643/4885ALDH1A1 3055/4885OGG1 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.